Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023
June 07 2023 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections, today announced that preclinical data from
Enanta’s out-licensing portfolio has been accepted for a poster
presentation at the European Association for the Study of the Liver
(EASL) International Liver Congress 2023 being held June 21 – 24,
2023 in Vienna, Austria at the Messe Wien Exhibition Congress
Centre.
In the poster, Enanta’s HSD17B13 inhibitors, which have
previously been shown to be anti-inflammatory in vivo with
modulation of sphingolipids, were evaluated in a mouse model of
autoimmune hepatitis for anti-inflammatory and hepatoprotective
effects.
Poster Title: “HSD17B13 Inhibitors are Hepatoprotective
and Anti-inflammatory in a Mouse Model of Autoimmune Hepatitis”
Final Abstract Identifier: FRI356 Day: June 23, 2023
Time: 9:00 a.m. – 6 p.m. CEST / 3 a.m. – 12:00 p.m. ET
Session: Immune-mediated and cholestatic: Experimental and
pathophysiology Presenter: Manuel Roqueta-Rivera, Ph.D.
The full scientific program for The International Liver Congress
2022, as well as the abstracts, can be found at
https://www.easlcongress.eu/.
About HSD17B13
17β-Hydroxysteroid dehydrogenase type 13, or HSD17B13, is a
lipid droplet associated enzyme expressed in the liver. Genome-wide
association studies have linked HSD17B13 to chronic liver diseases.
Enanta has generated novel potent and selective small molecule
inhibitors for this target for non-alcoholic steatohepatitis and
has utilized these compounds to probe the enzymology and structural
biology of HSD17B13, in addition to evaluating in vivo
efficacy.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections. Enanta’s research and development programs include
clinical candidates for the following disease targets: respiratory
syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus
(HBV). Enanta is also conducting research on a single agent
targeting both RSV and human metapneumovirus (hMPV).
Enanta receives royalties from hepatitis C virus (HCV) products
developed under its collaboration with AbbVie. Glecaprevir, a
protease inhibitor discovered by Enanta, is part of one of the
leading treatment regimens for curing chronic HCV infection and is
sold by AbbVie in numerous countries under the tradenames MAVYRET®
(U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please
visit www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230607005166/en/
Media and Investors Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024